Page last updated: 2024-09-04

tipifarnib and palbociclib

tipifarnib has been researched along with palbociclib in 6 studies

Compound Research Comparison

Studies
(tipifarnib)
Trials
(tipifarnib)
Recent Studies (post-2010)
(tipifarnib)
Studies
(palbociclib)
Trials
(palbociclib)
Recent Studies (post-2010) (palbociclib)
3099294911126864

Protein Interaction Comparison

ProteinTaxonomytipifarnib (IC50)palbociclib (IC50)
Chain B, Cell division protein kinase 6Homo sapiens (human)0.015
Chain B, Cell division protein kinase 6Homo sapiens (human)0.015
Cyclin-T1Homo sapiens (human)1.5085
Cyclin-KHomo sapiens (human)1.207
Cyclin-dependent kinase 1Homo sapiens (human)9.8
Cyclin-dependent kinase 4Homo sapiens (human)0.0109
G2/mitotic-specific cyclin-B1Homo sapiens (human)9.8
Cyclin-A2Homo sapiens (human)2.2042
AcetylcholinesteraseMus musculus (house mouse)0.021
G1/S-specific cyclin-D1Homo sapiens (human)0.0115
G1/S-specific cyclin-E1Homo sapiens (human)9.15
Cyclin-dependent kinase 2Homo sapiens (human)4.1887
G1/S-specific cyclin-D2Homo sapiens (human)0.0127
G1/S-specific cyclin-D3Homo sapiens (human)0.0194
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)3.48
Cyclin-dependent kinase 9Homo sapiens (human)1.1821
Tyrosine-protein kinase JAK3Homo sapiens (human)0.0631
Cyclin-dependent kinase 6Homo sapiens (human)0.018

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Bonovolias, ID; Chatzopoulou, M; Demopoulos, VJ; Nicolaou, I; Tsiftsoglou, AS; Vizirianakis, IS1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR1
Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR1
Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR1
Cavaco, BM; Leite, V; Lopes-Ventura, S; Marques, IJ; Matias, AT; Moura, MM; Pojo, M1

Reviews

1 review(s) available for tipifarnib and palbociclib

ArticleYear
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
    Journal of medicinal chemistry, 2010, Oct-14, Volume: 53, Issue:19

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Multipotent Stem Cells; Neoplastic Stem Cells; Pharmacogenetics

2010

Other Studies

5 other study(ies) available for tipifarnib and palbociclib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Highly predictive and interpretable models for PAMPA permeability.
    Bioorganic & medicinal chemistry, 2017, 02-01, Volume: 25, Issue:3

    Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine

2017
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
    Bioorganic & medicinal chemistry, 2019, 07-15, Volume: 27, Issue:14

    Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility

2019
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
    Scientific reports, 2020, 11-26, Volume: 10, Issue:1

    Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States

2020
The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
    Journal of endocrinological investigation, 2019, Volume: 42, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Gene Expression Regulation, Neoplastic; Humans; Mutation; Piperazines; Proto-Oncogene Proteins p21(ras); Pyridines; Quinolones; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Tumor Cells, Cultured

2019